Clinical trial NCT03868293: Low Intensity Focused Ultrasound Epilepsy: A Pilot Trial
Official title: Low Intensity Focused Ultrasound Treatment for Epilepsy: A Pilot Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Drug Resistant Epilepsy
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
First posted: 2019-03-11
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The aim of the proposed pilot study is to investigate patient tolerability and efficacy of moderate term, repeated exposure of Pulsed Low-Intensity Focused Ultrasound (PLIFUS) in patients with drug-resistant temporal lobe epilepsy.

Detailed description: The aim of the proposed pilot study is to investigate safety and tolerability of moderate term, repeated exposure of Pulsed Low-Intensity Focused Ultrasound (PLIFUS) in patients with drug-resistant temporal lobe epilepsy.

Due to the lack of options for patients with drug-resistant epilepsy, investigations into alternative noninvasive treatments are warranted. PLIFUS has been shown to safely modulate neuronal tissue, and is non-invasive and painless. Several human studies have shown that the use of PLIFUS can suppress somatosensory evoked potentials and induce functional magnetic resonance imaging (MRI) responses.

Once the subject is enrolled in the study, the subject will be scheduled for a standard brain MRI scan at BWH if they have not had one in the last 3 months. The subject will be asked to keep track of their seizure events in the Daily Seizure Log Diary from the screening visit until 6 months after the last treatment session.

The treatment period will include 6 treatment sessions total. These will occur 2 days per week for 3 weeks, each lasting approximately 1-2 hours, starting 1 month after seizure logging begins.

Eligibility criteria: Inclusion Criteria:

* Subjects at least eighteen (18) years of age
* Subjects with drug-resistant temporal lobe epilepsy whose seizures involve altered awareness (ie failed at least two trials of antiepileptic drugs for seizures), as determined by one of the BWH epilepsy neurologists based on clinical seizure semiology and/or EEG findings.
* Subjects who experience at least 1-2 seizures per month on average, are aware of or have reliable caregivers who are aware of when seizures occur and can reliably log seizure frequency
* Subjects who have the cognitive ability to read and understand the consent form, describe any potential symptoms experienced during or after treatments.

Exclusion Criteria:

* Subjects with a cognitive or psychiatric disorder that limits the ability to give informed consent or are unable to cooperate with testing
* Subjects with dementia or other progressive degenerative disease, delirium or active psychosis
* Subjects with ferromagnetic materials in the head
* Subjects with severe cardiac disease, increased intracranial pressure, or a Transcutaneous Electrical Nerve Stimulation (TENS) unit
* Subjects who have primary generalized epilepsy or non-epileptic seizures
* Subjects who have experienced status epilepticus in the 3 months leading up to enrollment in the study
* Subjects (females) who are pregnant, or are of childbearing potential and not willing to use reliable birth control during the treatment period.
* Subjects who are unable to get a brain MRI for any reason (implanted metal in body, inability to lie still)
* Subjects with current brain tumors or an intracranial vascular lesion
* Subjects with severe, uncontrolled medical problems, such as diabetes mellitus, hypertension, pulmonary or airway disease, heart failure, coronary artery disease, or any other condition that poses a risk for the subject during participation.
* Subjects with holes in the treatment area of the skull from trauma or prior surgery
* Subjects with pacemakers, medication pumps, and other implanted electronic hardware. If a subject has a working Vagal Nerve Stimulator in place, the device will be turned off prior to each treatment session and then turned back on after each session.

Primary outcomes:
measure: Patient tolerability of moderate term, repeated exposure toPulsed Low-Intensity Focused Ultrasound (PLIFUS) (Adverse Events assessment)
timeFrame: 3 months
measure: Efficacy of PLIFUS in reducing seizure frequency
timeFrame: 3 months
measure: Effect of PLIFUS on patient EEG (evaluate number of attenuated epileptiform discharges)
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Brigham and women's Hospital
state: Massachusetts
Study officials:
affiliation: Brigham and Women's Hospital
name: Ellen J Bubrick, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bubrick EJ, McDannold NJ, White PJ. Low Intensity Focused Ultrasound for Epilepsy- A New Approach to Neuromodulation. Epilepsy Curr. 2022 Mar 29;22(3):156-160. doi: 10.1177/15357597221086111. eCollection 2022 Jun.